Has Glenn Yiu, MD received payments from drug or device companies?

Yes. Drug and device makers reported $146,385 in general payments to Glenn Yiu, MD across 126 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Glenn Yiu, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Glenn Yiu, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Glenn Yiu, MD

Retina Specialist · Sacramento, CANPI 1730348921

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $131,303 of the $146,385 with a category attached, or 89.7%. 22 manufacturers reported payments, led by AbbVie at 45.8% of the total. Among retina specialist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$146,385in general payments, 2019–2025

Across 126 payments — averaging $1161.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$67K
Genentech USA, Inc.$16K
Bausch & Lomb Americas Inc.$13K
Merck$12K
Alcon Research LLC$10K
Genentech, Inc.$7K
plus $21K from 16 others

$539,652in research payments, 2019–2025

Across 75 payments — averaging $7195.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Genentech, Inc.$502K
Regeneron$22K
F. Hoffmann-la Roche AG$16K

What the payments were for

Consulting fees$131,30390%
Speaking & faculty fees$4,8683%
Travel & lodging$6,2594%
Food & beverage$3,9483%
Entertainment$70%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	33	$67,034
Genentech USA, Inc.	16	$16,352
Bausch & Lomb Americas Inc.	24	$13,336
Merck	13	$11,608
Alcon Research LLC	3	$10,242
Genentech, Inc.	7	$6,925
Boehringer Ingelheim	2	$4,790
Iridex Corporation	2	$3,750
Regeneron	1	$2,780
Samsung Bioepis Co., Ltd.	2	$1,800
Janssen Research & Development, LLC	1	$1,600
Cardinal Health 108 LLC	1	$1,575
Alimera Sciences, Inc.	2	$1,085
Alcon	5	$985
F. Hoffmann-la Roche AG	1	$880
Carl Zeiss Meditec, Inc.	2	$620
Novartis	4	$465
Apellis Pharmaceuticals, Inc.	3	$275
Cardinal Health 110 LLC	1	$150
Astellas Pharma US Inc	1	$99
Astellas Pharma Global Development	1	$28
Optos, Inc.	1	$7

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

XIPERE$12,943
SUSVIMO$11,577
Lucentis$7,614
VABYSMO$4,717
EYLEA$2,780
Iluvien$1,000
E301$900
OZURDEX$775
CIRRUS HD-OCT$550
CLARUS$550
FORUM$550
Humphrey HFA$550
BEOVU$234
Syfovre$105
Hydrus Microstent$102

How this compares

$146,385 in reported general payments places this provider in the 90th percentile of 187 retina specialist providers in California.

See all retina specialist providers in California →

Medicare billing

Part B allowed, 2024

$155,564

Medicare patients

413

Services billed

2,365

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prednisolone Acetate	24	$940
Difluprednate	11	$874

Paid to pharmacies, not to this prescriber.

Other retina specialist in Sacramento

Carlos Medina MendezSacramento$548K
Margaret ChangSacramento$197K
Joel PearlmanSacramento$33K
David TelanderSacramento$18K
Maryam GhiassiSacramento$10K
Dilsher DhootSanta Barbara$1.9M
Ehsan RahimyStanford$1.5M
Darius MoshfeghiPalo Alto$1.4M
Nathan SteinleSanta Barbara$1.1M
Roger GoldbergWalnut Creek$1.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →